retatrutide phase 2 trial obesity nejm 2023 in adults with over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 Retatrutide hits 28% weight loss

Needle-free support: Many people hope for an option that does not involve a needle

Comparing intranasal retatrutide to other nasal peptides Intranasal retatrutide is not the first peptide to be explored through nasal delivery

Here is what the letter said, and what it did not say

The body may still be adapting to: Weight loss Appetite suppression Lower calorie intake Hydration changes Hormonal shifts However, severe or persistent fluctuations should not be ignored

Medication and Side Effect Monitoring Keep track of medication usage and side effects associated with Ozempic, Wegovy, Mounjaro, and other GLP-1 options

Participants ranged in age from 18 to 70 years, with females surpassing males in most trials